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ABSTRACT
When considering the clinical applications of autologous cell replacement therapy of human
induced pluripotent stem cells (iPSC)-derived cells, there is a clear need to better understand what
the immune response will be before we embark on extensive clinical trials to treat or model human
disease. We performed a detailed assessment comparing human fibroblast cell lines (termed F1)
reprogrammed into human iPSC and subsequently differentiated back to fibroblast cells (termed F2)
or other human iPSC-derived cells including neural stem cells (NSC) made from either retroviral,
episomal, or synthetic mRNA cell reprogramming methods. Global proteomic analysis reveals the
main differences in signal transduction and immune cell protein expression between F1 and F2 cells,
implicating wild type (WT) toll like receptor protein 3 (TLR3). Furthermore, global methylome analy-
sis identified an isoform of the human TLR3 gene that is not epigenetically reset correctly upon
differentiation to F2 cells resulting in a hypomethylated transcription start site in the TLR3 isoform
promoter and overexpression in most human iPSC-derived cells not seen in normal human tissue.
The human TLR3 isoform in human iPSC-NSC functions to suppress NF-KB p65 signaling pathway in
response to virus (Poly IC), suggesting suppressed immunity of iPSC-derived cells to viral infection.
The sustained WT TLR3 and TLR3 isoform overexpression is central to understanding the altered
immunogenicity of human iPSC-derived cells calling for screening of human iPSC-derived cells for
TLR3 expression levels before applications. STEM CELLS 2019;37:476–488
SIGNIFICANCE STATEMENT
The cell reprogramming process alters the immune response of most induced pluripotent stem
cells (iPSC)-derived cells highlighting human toll like receptor protein 3 (TLR3) isoform overex-
pression that functions to suppress innate immune signal transduction and provides an insight
for future clinical applications of autologous human iPSC-derived cell transplantation. The
authors propose that screening human iPSC clones and their derived cells for alterations in the
genome of patient cells that include expression levels of human TLR3 and its shorter TLR3 iso-
form identified in this work is essential before embarking on “first in man” clinical trials or
human disease modeling using human iPSC.
INTRODUCTION
The discovery of methods to reprogram somatic
human cells into tissue specific adult stem cells
directly or by full reprogramming, to produce
induced pluripotent stem cells (iPSC) has pre-
sented the possibility of an easy and abundant
source of cells for autologous stem cell therapy
to treat many human diseases [1–3]. Three
major challenges that must be overcome before
reprogrammed stem cells can be used for clinical
applications are genetic instability, proper differ-
entiation to relevant cell types to regenerate
damaged tissues and the immune response of
transplanted cells. The interaction of the human
immune system with autologous reprogramed
human cells remains an unexplored question.
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It is well accepted that Toll receptors are a major part of the
innate immune system essential for life [4]. Likewise, regulation of
inflammation cytokines by toll-like receptor 3 (TLR3 - virus) and
toll like receptor 4 (TLR4 - bacteria) is well established [5, 6].
Recent publications in animal studies (mice and non-human pri-
mates) indicate that there may be some immune response to
autologous reprogramed cells [7–14]. A recent review identi-
fied that many aspects of the adaptive and innate immune sys-
tem mechanisms are yet to be explored in detail for human
cells [3, 15]. Data from human transplanted autologous repro-
gramed cells in vivo is limited and only one current clinical trial
for iPSC-RPE cells exists that found edema in the patient retina
most likely from the surgical intervention for the transplanted
iPSC-RPE cell sheet [16–19]. As the field grows and moves
closer to clinical application the need to understand the extent
of the immune response to transplanted human iPSC-derived
cells becomes paramount.
Of the studies conducted to date in mouse models on the
immune response to autologous iPSC-derived cells, the group
from Zhao et al. (2011) studied the immunogenicity of both ret-
roviral vector reprogrammed mouse iPSC and episomal vector
reprogrammed integration free mouse iPSC. They transplanted
the mouse cells under the skin to evaluate the immunogenicity
of mouse iPSC-derived cells in syngeneic mice and found
issues with immogenicity [8]. Studies that transplanted mouse
iPSC-derived cells into the neural system and kidney found no
apparent immunogenicity [7, 9]. Further work by Todorova et al.
identified one possible mechanism underlying these conflicting
conclusions [14]. They show that the lack of immunogenicity of
mouse iPSC-derived cells in syngeneic host when transplanted
into the kidney is due to the absence of functional antigen
presenting cells in mouse kidney, highlighting that the site of
iPSC-derived cell transplantation in vivo is important in experi-
mental design [14]. A more recent study was performed in
non-human primates testing iPSC-derived neurons found no
major immune response, although a small immune response
was observed [10]. In the study by Zhao et al. (2015), iPSC-derived
smooth muscle cells and retinal pigmented epithelial cells were
transplanted into humanized mice reconstituted with autolo-
gous human immune system, demonstrating differential immu-
nogenicity in vivo [12]. Interestingly, IL10 secretion from mouse
iPSC-derived cells has been found to suppress the immune
response, and IL10 is known to suppress the activity of activated
T cells, suggesting a mechanism for iPSC-derived cells to by-pass
immune system to survive and engraft [11].
There is a clear need to better understand what the
immune response to human autologous reprogramed cells will
be before we embark on extensive clinical trials to treat
human disease. We have performed a detailed global proteo-
mic and methylome analysis of the possible immune response
of matched human patient fibroblast cells (termed F1) repro-
gramed to iPSC and compared to iPSC-derived cells (termed F2)
for retroviral, episomal, and synthetic mRNA transfection methods
to reprogram human fibroblasts to human iPSC. The data shows
that in most aspects the immune biology is similar for either viral
or non-viral made iPSC-derived cells; however, a significantly dif-
ferent higher expression of wild type (WT) human TLR3 in iPSC
derived cells. Global methylome analysis in synthetic mRNA made
human iPSC revealed a shorter isoform of human TLR3 is over
expressed in human reprogrammed cells (the TLR3 isoform is
not expressed in mice) not seen in normal human physiological
tissues or cells. We confirm in three retroviral made and three
episomal made human iPSC from healthy control patient cells
that the TLR3 isoform is over expressed in five from six matched
pairs of cells (approx. 85% of human iPSC overexpress the
human TLR3 isoform). We show that the human TLR3 isoform
functions to suppress NF-KB p65 signaling pathway in response
to virus (Poly IC), suggesting suppressed immunity of human
iPSC-derived cells to viral infection. Taken together the data
demonstrate that the cell reprogramming process alters spe-
cific aspects of the immune response of in vitro generated
human iPSC-derived cells, suggesting a reduction of innate immu-
nogenicity of human iPSC-derived cells, calling for screening of
human iPSC clones for human TLR3 expression levels before use
in disease modeling or clinical applications.
MATERIALS AND METHODS
iPSC Cell Culture
Established human iPSC clones were obtained from collaborators
for this project and previously published. Six human skin fibroblast
cell lines (termed F1) that have previously been reprogrammed into
iPSC, three by retroviral methods [2, 20, 21] and three by non-viral
episomal methods [22] were used. Synthetic mRNA reprogramming
to iPSC was performed using Stemgent’s microRNA-enhanced
mRNA reprogramming kit (STEMGENT, #00-0071, UK) protocol
using Thermo Fischer defined cell culture media products. Differen-
tiation to various cell lines and the mRNA transfection method is
described in full in a separate manuscript. All hiPSC were differenti-
ated between passages 10–15. Feeder-free “clinical grade” synthetic
mRNA iPSC were cultured in defined Flex E8 culture medium (Life
Technologies, A2858501, Spain) on Vitronectin (Life Technologies,
A14700, Spain) coated plates. Colonies were passaged by gentle dis-
sociation with 0.5 mM EDTA when they were 75%–80% confluence.
Cell culture conditions for hiPSC can be found for Episomal and Ret-
roviral made hiPSC in the papers from Refs. 20–22.
Proteomic Analysis for Global and MHC-1 Peptide
Analysis
Protein Solubilization and Quantification. Protein solubiliza-
tion was performed independently for each of the eight pel-
leted cell samples, five with patients fibroblasts (F1) and three
with iPSC-fibroblasts (F2), with 1% (vol/vol) SDS lysis buffer.
To eliminate viscosity, the lysates were heated to 60C for
15 minutes and sonicated at 45% amplitude for 4 seconds.
Protein concentration of each sample was estimated using
BCA Reagent Compatible kit (Thermo Scientific, Rockford, IL)
following the manufacturer’s instructions.
Peptides Preparation and Labeling with Isobaric Tags (Tandem
Mass Tag 10-Plex). For global analysis, 50 g of proteins from
each sample were digested and labeled with tandem mass tag
(TMT) 10-plex isotopic label reagent set (Thermo Scientific,
Rockford, IL) following the manufacturer’s instructions. Nine of
the 10 TMT label reagents (tags: 126; 127N; 127C; 128N; 128C;
129N; 129C; 130N; 131) were used. For normalization purposes,
an internal control consisting on a mixture of 6.25 g of each of
the eight samples was included and labeled with TMT126. The
TMT labeled samples including control were then combined at
a 1:1:1:1:1:1:1:1:1 ratio. Mixture of samples was cleaned by
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Pierce C18 Spin columns (Thermo Scientific, Rockford, IL) and
stored at −80C.
Liquid Chromatography–Tandem Mass Spectrometry
For global analysis, labeled peptides were separated by means
of nanoliquid chromatography using a nanoLC ULTRA AS2
(Eksigent, Australia) with a flow rate of 400 nl/min, a C18 Pep-
map 100 trap column (5 μm, 100 Å, 300 μm i.d. × 5 mm in
length), and an Acclaim PepMap C18 analytical column (3 μm,
100 Å, 75 μm i.d. × 15 cm in length).
The following linear gradient, using solvent B (97% ACN,
0.1%formic acid) and solvent A (3% ACN, 0.1% formic acid), was
used: 5%–30% buffer B (140 minutes). MS/MS analysis was per-
formed using an LTQ Orbitrap Velos (ThermoFisher Scientific,
Rockford, IL) with a nanoelectrospray ion source with precursor
ion selection in the Orbitrap at 30,000 of resolution, selecting
the 20 most intense precursor ions in positive ion mode. MS/MS
data acquisition was completed using Xcalibur 2.1 (ThermoFisher
Scientific, Rockford, IL). For identification of TMT labeled pep-
tides, higher energy collisional dissociation (HCD) with 40% fixed
collision energy was the fragmentation method used.
Protein Identification and Quantification
Data was processed using Proteome Discoverer 1.4.1.14
(Thermo Fisher Scientific, Rockford, IL). For database searching,
raw mass spectrometry files were submitted to the in-house
Homo sapiens UniProtKB/Swiss-Prot database (released 2015-02;
20,165 protein entries) using SEQUEST (Thermo FisherScientific,
Rockford, IL). The Percolator search node, a machine-learning
supplement to the SEQUEST search algorithm that increases the
sensitivity and specificity of peptide identifications, was also
used. Searches were performed using the following settings:
2 maximum miss cleavage for trypsin, TMT-labeled in N-Termi-
nal, lysine (+229.163 Da) and methionine oxidation (+15.995 Da)
as dynamic modifications, cysteine carbamidomethylation
(+57.021 Da) as static modification, 20 ppm precursor mass toler-
ance, 0.05mmu fragment mass tolerance, 5mmu peak integration
tolerance, and most confident centroid peak integration method.
The criteria used to accept protein identification included a mini-
mum of two peptides matched per protein, with a false discovery
rate of 1%. To avoid the possible ambiguity associated with dif-
ferent isoforms of the same protein during the quantification, all
of the proteins were treated as ungrouped.
Quantitative analysis of the TMT experiments was per-
formed simultaneously to protein identification using Prote-
ome Discoverer software. Peptide spectral matches (PSMs)
were filtered by PD1.4 software with parameters: Min. Precur-
sor Mass: 300 Da, Max. Precursor Mass: 5,000 Da. Reporter
ion quantification of HCDMS2 spectra was enabled, and TMT-
10 plex was set as quantification method. To avoid overlap
between the isobaric reporter ions a resolution greater than
60,000 was used from m/z 126.1 to m/z 131.1. The quantifica-
tion values were extracted from the ration between the
reporter ions intensities (in; where n represents the reporter
ions ranging from m/z 127.1 to m/z 131.1) and the reporter ion
intensity from m/z 126.1, and were corrected according to the
isotopic purities of the reporter ions provided by the manufac-
turer. Quantification values were rejected whenever any quanti-
fication channel was missing or whenever variability of the
reporter intensity was higher than 50% among the different
PSMs of the same protein. For protein quantification purposes,
only unique peptides were considered, and protein ratios were
normalized to protein median. Normalized values for each pro-
tein were exported to Microsoft Excel (v14.0.0), and only those
proteins with quantification values for all of the samples
(i.e., eight samples and the internal control) were considered
for further analysis.
Illumina Infinium Methylation EPIC BeadChip
All DNA samples were assessed for integrity, quantity, and
purity by electrophoresis in a 1.3% agarose gel, picogreen
quantification, and nanodrop measurements. Bisulfite conver-
sion of 500 ng of genomic DNA was performed using EZ DNA
methylation kit (Zymo Research. Irvine) following manufac-
turer’s instructions. Bisulfite (200 ng) converted DNA were
used for hybridization on the Illumina Infinium Methylation-
EPIC BeadChip (Illumina, Inc. San Diego). Briefly, samples were
whole genome amplified followed by an enzymatic end-point
fragmentation, precipitation, and resuspension. The resus-
pended samples were hybridized onto the beadchip for 16 hours
at 48C and washed. A single nucleotide extension with labeled
dideoxy-nucleotides was performed and repeated rounds of
staining were applied with a combination of fluorescently labeled
antibodies differentiating between biotin and DNP. Fluorescent
signal from the microarray was measured with a HiScan scanner
(Illumina, Inc. San Diego) using iScan Control Software (V 3.3.29).
A three step-based normalization procedure was performed
using the lumi [23] package available for bioconductor [24],
under the R statistical environment, consisting in color bias
adjustment, background level adjustment and quantile normali-
zation across arrays, as specified in [23]. Methylation level
(β-value) for each of the 866,836 CpG sites were calculated as
the ratio of methylated signal divided by the sum of methylated
and unmethylated signals plus 100. All beta values with an asso-
ciated p value greater or equal to 0.01 were removed from the
analysis.
Bisulfite Pyrosequencing
To validate the methylome array, we performed bisulfite pyrose-
quencing following published protocols [25]. Briefly, specific set of
primers for PCR amplification and sequencing were designed using
the PyroMark assay design program, version 2.0 (Qiagen, Nether-
lands); amplification primers hybridize with CpG-free sites to
ensure a methylation-independent reaction and one primer
(opposite the sequencing primer) is biotinylated to convert
the PCR product to single-stranded DNA templates. We used
1 μl of bisulfite-treated DNA for each PCR. The EZ DNA methyl-
ation kit (Zymo Research, Irvine) was used for bisulfite conver-
sion of all DNA samples used [25]. To prepare single-stranded
PCR products, we used the Vacuum Prep Tool (Qiagen, Neth-
erlands), following the manufacturer’s instructions. Pyrose-
quencing reactions and methylation quantification were
performed in a PyroMark Q24 System version 2.0.6 (Qiagen,
Netherlands).
Sequencing
Human TLR3 isoform was sequenced using 50 ng of DNA follow-
ing a BigDye protocol published by the University of Pompeu
Fabra Genomics Core Facility in Barcelona. Primers used listed
in Supporting Information Figures.
©2019 The Authors. STEM CELLS published by
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Lipopolysaccharide and Poly (I:C) Stimulation
F1 and F2 cells were seeded in 24-well plate and once 80% con-
fluent they were stimulated with 100 ng/ml lipopolysaccharides
(LPS) and 1 μg/ml Polyinosinic:polycytidylic acid, (Poly(IC)), to
stimulate an innate immune response. After 24 hours superna-
tants were collected and analyzed with an ilumina cytokine
kit. Cells were also pelleted and protein lysates were extracted
and separated into cytoplasmic and nuclear fraction.
Cytoplasmic and Nuclear Protein Fraction Extraction
Cells were resuspended on 80 μl of Buffer A (HEPES 10 mM
pH 7.9, KCl 10 mM, MgCl2 1.5 mM, DTT 1 mM) with protease
inhibitors (PMSF 0.5 mM, aprotinin 5 μg/ml, leupeptin 2 μg/ml,
sodium pyrophosphate decahydrate 2 mM, sodium beta-
glycerophosphate pentahydrate 2 mM, sodium orthovanadate
1 mM). It was kept on ice for 15 minutes, then NP40 0.6% was
added and centrifuged 30 seconds 16,000g at 4C. The superna-
tants (cytoplasmic fraction) were transferred to a new tube. Cell
pellets (nuclear fraction) was resuspended in 50 μl of Buffer B
(HEPES 20 mM pH 7.9, NaCl 0.46 M, EDTA 1 mM, EGTA 1 mM,
DTT 1 mM) with PMSF.
Illuminex Cytokine Detection Array
Cytokine levels were assessed by Luminex (Millipore, Billerica,
MA) following the manufacturer’s instructions. Briefly, superna-
tants were incubated for 2 hours with corresponding anticyto-
kine magnetic beads, and then washed with 1× washing buffer
and stained with detection antibodies (provided) for 1 hour.
Strepatividin-PE was then added for 30 more minutes. During all
incubation steps, the plate was agitated at 650 rpm. After wash-
ing, plate was agitated for 15 minutes at 650 rpm and read in
the xMAP Luminex reader (Waltham, MA).
Lentiviral Production
Human WT TLR3 Lentiviral Vector was purchased (pLenti-GIII-
UbC) (Abcam, LV335740, Cambridge, UK) and was used to over-
express human TLR3 full length in iPSC-derived neural stem
cells (NSC). Viral particles were produced with a 293T packag-
ing cell line. NSC were infected once with viral supernatants. At
day 3, infected NSC were selected with puromycin for 7 days
and placed in experiments. Overexpression of TLR3 was checked
by RT-PCR, FACS, and Western blot.
Western Blot
Protein extracts of cells collected by centrifugation, washed twice
in PBS, lysed in 1× lysis buffer (50 nM Tris–HCl, 70 mM
2-mercaptoethanol, and 1% SDS) and the concentration of total
protein was measured by the Bradford assay. Lysates were then
boiled for 5 minutes, and subjected to 12% polyacrylamide SDS
gels or 4%–12% SDS resolving gels (Invitogen). After electropho-
resis, proteins were transferred to a nitrocellulose membrane
using a submerged transfer apparatus (BioRad), filled with
25 mM Tris Base, 200 mM glycine, and 20% methanol. After
blocking with 5% non-fat dried milk in TBS-T (50 mM Tris–HCl
[pH 8.0], 150 mM NaCl, and 0.1% Tween 20) the membrane
was incubated with the primary antibodies diluted in TBS-T and
washed extensively. For the list of primary antibodies used see
Supporting Information Figure S10. The membrane was washed
3 times with TBS-T and then incubated with the appropriate
horseradish peroxidase linked secondary antibody (Amersham,
Spain). The detection was performed with the Western Breeze
Immunodetection Kit (Invitrogen, Spain).
Flow Cytometry
Cells were stained with antibodies listed in figures. All analyses
were performed with a BD FACSCanto-II flow cytometer or
MoFlo cell sorter (Dako Cytomation, USA) running Summit soft-
ware. See Supporting Information Figure S9 for list of anti-
bodies used.
Real Time PCR
Total mRNA was isolated using TRIZOL and 1 ug was used to
synthesize cDNA using the Invitrogen Cloned AMV First-Strand
cDNA synthesis kit. One to two ul of the reaction was used to







































TLR3 isoform RT-PCR primers were tested in both human
foreskin fibroblasts (HFF) cells and NSC with R2 of 0.78465 and
0.92829, respectively (Supporting Information Fig. S10). All
other primer sets are previously published.
Statistical Analyses
Unpaired nonparametric t tests were used to evaluate statistical
significance at p ≤ .05. All quantitative and qualitative analyses
are representative of at least n = 3 biological repeats for all
experiments to give significant statistical power for reliability and
validity of data. Only significantly different data in the figures
are given a p value. Differential Protein Annotation and Bioinfor-
matics Analyses: Proteins identified in different amounts in each
of the two experiments were analyzed using the bioinformatics
tool DAVID v6.7 (Database for Annotation, Visualization and Inte-
grated Discovery; http://david.abcc.ncifcrf.gov/) to identify over-
represented biological pathways [26, 27]. Similarly, differential
proteins were analyzed for protein–protein interaction networks
using the online tool STRING v10 [28]. To determine differentially
expressed quantified proteins between the groups (F1 vs. F2) for
small peptide analysis, statistical analysis was carried out using
SPSS for Windows (version 21.0, Chicago, IL). All variables were
checked for Levene’s test to check variance homogeneity. Com-
parison between groups (i.e., F1 vs. F2) was performed using
Student’s t test. p ≤ .05 was considered to be significant.
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RESULTS
Global Proteomic Analysis of Patient (F1) and
iPSC-Derived Fibroblasts (F2)
Six human skin fibroblast cell lines (termed F1) that have previ-
ously been reprogrammed into iPSC, three by retroviral methods
[2, 20, 21] and three by non-viral episomal methods [22], then
differentiated back to fibroblasts (termed F2) were analyzed for
their potential immune response (Fig. 1A).
First, we performed a global proteomic analysis comparing
F1 to F2 cells and mapped the protein expression profile.
Overall, we detected 1,508 quantifiable proteins of which 86 pro-
teins differed significantly in the expression levels between F1
and F2 cells (Supporting Information Figs. S1, S2). Categorizing
proteins based on function, we first demonstrate no significant
difference in fibroblast markers CD90, Fibronectin and CD44
between F1 and F2 cells, indicating that they are similar
fibroblast cell populations for both viral and non-viral made
iPSC-derived cells (Fig. 1B). CD90, CD44, and Fibronectin are
established markers of fibroblasts as defined by Pilling et al.
[29]. The main differences in protein expression in F2 cells are
signal transduction, cell cycle, and immune system proteins
Figure 1. Global proteomic analysis of patient (F1) and human iPSC derived fibroblasts (F2). (A): Panels left to right: Photos representative
of the healthy control human fibroblasts termed F1 (human skin fibroblasts), iPSC clone (from previously published studies), differentiation
to embryoid bodies and iPSC-derived fibroblasts, termed F2, at two different passages. A total of six sets of normal healthy control patient
cells from previously published studies were used: three RV and three EPI (×100). Five F1 (n = 5) and three F2 (n = 3) cell populations was
analyzed for proteomics between passage 3 to 9. (B): Table showing proteins characteristic of human MSC, hematopoietic cells and fibro-
blasts that have either been identified or not in the F1 and F2 cells. The p value indicates that there is no difference in the amount of these
proteins between F1 and F2 indicating that the F1 and F2 cell types are similar. (C): Table showing the differential proteins between F1 and
F2 involved in the immune response according to Reactome and Panther. (D): Table showing the differential proteins between F1 and F2
involved in signal transduction according to Reactome. (E): Schematic diagram of the main pathways overrepresented (in yellow) of all pro-
teins detected (Reactome). (F): Interactions among the differential proteins involved in signal transduction and the TLR3, TLR4, IL6, and CCL2
proteins (highest confidence = minimum interaction score of 0.900). (G): Interactions among the differential proteins involved in immune
system and the TLR3, TLR4, IL6, and CCL2 proteins (highest confidence = minimum interaction score of 0.900). (H): Validation of proteomic
screen in three (n = 3) F1 and three F2 cell populations by flow cytometry for fibroblast markers CD90, CD44 and negative control marker
CD34 (MSC marker) in F1 and F2 cells, demonstrating that the two populations of fibroblasts are similar. (I): Validation of proteomic screen
in three (n = 3) F1 and three F2 cell populations by Western blot for signal transduction proteins AKT Ser 478, total AKT and loading control
Actin. Two from three matched pairs of cells demonstrated increased AKT signaling in F2 cells (EPI-2 the exception, see Fig. 4B). Abbrevia-
tions: EPI, episomal made iPSC; iPSC, induced pluripotent stem cells; MSC, mesenchymal stem cells; RV, retroviral made iPSC.
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(Fig. 1C–1G; Supporting Information Fig. S1A). Interestingly, the
proteomic screen revealed many proteins interacting with the
TLR3 and TLR4 pathway (Fig. 1F, 1G).
To verify the global proteomic analysis, we performed flow
cytometry analysis of the F1 and F2 populations and confirmed
that the two fibroblast cell populations are similar for two
fibroblast cell markers CD90, CD44 and negative for stem cell
marker CD34 (Fig. 1H). This was the same for retrovirally made
iPSC-derived cells or non-virally made iPSC-derived cells and so
they are both grouped together (Supporting Information Fig. S3).
Given that signal transduction proteins were the most represented
differentially expressed proteins between F1 and F2 cells, we
also verified that signal transduction pathways for AKT is over
expressed in F2 cells compared to F1 cells by Western blot
analysis (Fig. 1I). We next assessed the immune response given
the differences identified in the proteomic screen.
Characterization of Adaptive and Innate Immune
System in Human iPSC
Analysis of HLA type by deep sequencing methods was per-
formed to confirm the HLA type for all cell types used (Fig. 2A).
MHCI mRNA gene expression (HLA-A, B, C, and B2M) for F1, iPSC
and F2 cells by RT-PCR and demonstrates no significant change
in expression between F2 cells and F1 cells (Fig. 2B), supported
by similar results in a previously published report [30]. MHC-1
protein expression was assessed by flow cytometry in all F2 cell
lines and no significant difference in expression levels of MHCI
was observed. Expression of MHC-1 was not significantly different
between retrovirally made iPSC-derived cells (RV1-3) and non-
virally made iPSC-derived cells (Epi1-3) (Fig. 2C).
To mimic the possible in vivo functional response, we
assessed MHCI expression response to inflammation cytokine
INF-gamma (10 ng/ml over 24 hours) in F1 and F2 cells from
Figure 2. Characterization of adaptive and innate immune system in human iPSC. (A): Genotype of the HLA of the six control healthy
patient human fibroblasts (n = 6) previously reprogramed into hiPSC in other published studies. (B): Graph of the RT-PCR HLA gene expres-
sion levels (n = 6) in healthy control patient fibroblasts (F1), subsequent iPSC clones and iPSC-derived fibroblasts (F2) demonstrating no dif-
ference in HLA gene expression between F1 and F2 cells. (C): Flow cytometry histograms of the six patient iPSC derived fibroblasts
(F2) (n = 6) for MHC-I protein expression in three RV and three EPI. (D): Graph representing expression levels of MHC-I (n = 3) by flow cyto-
metry for F1 cells and F2 cells stimulated with 10 ng/ml INF-gamma overnight. (E): Table of RT-PCR analysis of TLR3 gene expression levels
in F1 and F2 cells of pairs of cells (n = 10) demonstrating that the wild type (WT) human TLR3 gene is overexpressed between twofold and
ninefold more cells in F2 iPSC-derived cells in eight from 10 matched healthy cells (80%). (F): Representative flow cytometry histograms of
F1 and F2 cells stained for TLR3 receptor expression confirming that WT human TLR3 is overexpressed in twofold to fivefold more cells in F2
cells for one RV-made pair, one EPI-made pair (for RV and EPI, F1 and F2 cells are fibroblasts) and one synthetic mRNA made iPSC-made pair
(F1 are HFF cells and F2 are neural stem cells) (n = 3). Abbreviations: EPI, episomal made iPSC; HLA, human leukocyte antigen; iPSC, induced
pluripotent stem cells; MHC, major histocompatibility complex; RV, retroviral made iPSC; TLR3, toll like receptor protein 3.
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both viral and non-viral made iPSC by flow cytometry. Both F1
and F2 cells responded with an upregulation of MHCI expres-
sion in response to INF-gamma and there was no significance
difference indicating that the regulation of MHCI expression is
not affected in iPSC derived cells (Fig. 2D, Supporting Informa-
tion Fig. S4). This suggests further that MHCI expression is
functionally normal in iPSC-derived cells.
To further characterize the F1 and F2 cells, we analyzed
the expression of small peptides presented by MHC-1 using
mass spectrometry for RV1 clone that revealed differences in
the number and type of small peptide expressions between F1
and F2 cells that could implicate functional differences in the
adaptive immune response of transplanted iPSC-derived cells
(Supporting Information Fig. S5).
We next analyzed the innate immune response by asses-
sing the expression of 25 cytokines routinely assed by clinical
immunologists using the ELISA method in two matched cell
lines (F1 vs. F2 cells) for viral (RV) or non-viral (EPI) made iPSC
derived cells, with or without viral ligand stimulation (Poly lC)
or bacterial ligand stimulation (LPS) identified the main cyto-
kines involved (Supporting Information Fig. S6A). Further anal-
ysis in another focused cytokine array (six cytokines) assessing
four matched iPSC lines (F1 vs. F2 cells), we found no signifi-
cant difference in expression of cytokines between viral and
non-viral made F2 cells when compared to F1 cells. In general,
we found high variation between patient cell lines in cytokine
levels that suggested altered expression in F2 cells (Supporting
Information Fig. S6).
We found proteins associated with the innate immune sys-
tem with higher WT human TLR3 and WT TLR4 expression
found in the proteomic screen in F2 cells (Fig. 1) suggesting a
dysfunctional innate cell signaling pathway, prompted us to
investigate further human TLR3 expression levels in the healthy
patient control matched F1 and F2 cells (Fig. 1, Supporting Infor-
mation Figs. S1, S2). We observed that four from five patient
(80%) control F1 matched F2 cells have increased TLR3 gene
expression in F2 cells by RT-PCR analysis (Fig. 2E, Supporting
Information Fig. S7B). We next confirmed by flow cytometry
analysis TLR3 receptor protein expression is independent of
method used to reprogram cells and overexpressed in F2 cells
(Fig. 2F). Taken together the data demonstrate that the WT
TLR3 receptor expression is higher in healthy patient control
iPSC-derived cells, suggesting that reprogramed cells have an
altered TLR3 pathway.
Human TLR3 Isoform Transcription Start Site Is
Hypomethylated in Human iPSC-Derived Cells and
Exclusively Expressed in Humans
To investigate further the increase in TLR3 expression in a
wide range of iPSC-derived cell types, we reprogrammed using
non-viral synthetic mRNA transfection methods HFF (F1) and
characterized six iPSC clones differentiated to various cell types
(F2) (iPSC characterization data in a separate submitted paper)
(Figs. 3–5). We then performed a methylome array to further
characterize and better define the differences between F1 and
F2 cells (Fig. 3A). Using the following bioinformatic criteria:
(a) more than 20% difference in CpG methylation levels, (b) more
than one CpG island affected, and (c) at least two hiPSC clones
affected, we analyzed the methylation levels for Toll-like recep-
tors (Fig. 3B). Interestingly, the methylome array detected that a
transcription start site (TSS) site in the CpGs of a shorter genetic
isoform of full length TLR3 gene, and not other TLR gene family
members (Supporting Information excel methylome data), is
hypomethylated in human iPSC and derived NSC (F2), not seen
in the starting parent HFF cells (F1) (Fig. 3B). We confirmed the
CpG hypomethylation of the TLR3 isoform by bisulfide pyro-
sequencing (Fig. 3C, Supporting Information Fig. S7). Bioinfor-
matics analysis of the human TLR3 WT and TLR3 Isoform
demonstrate that the TSS site is associated with Acetylation and
DNAse hypersensitivity sites associated with gene expression and
that the TLR3 isoform is uniquely expressed in humans and not
in mice or rat (Fig. 3D, 3E).
Human TLR3 Isoform Is Overexpressed in Most Human
iPSC-Derived Cells Not Seen in Normal Human Tissue
or Cells
We next assessed gene expression levels of human TLR3 iso-
form in human F1 and F2 cells from the healthy patient con-
trol cells (Episomal and Retroviral) described in Figures 1 and 2
and the synthetic mRNA made human iPSC cells described in
Figure 3. We next performed PCR of genomic DNA for sequenc-
ing in F2 cells from synthetic mRNA made human iPSC-derived:
NSC and cardiomyocytes (CM) to demonstrate the unique 50
UTR of the human TLR3 isoform in F2 cells. Sequencing data of
the PCR product for the 50 UTR confirms the human TLR3 iso-
form (in Red) in human F2 cells with whole sequence found at
UC011CKZ.2 or XM_017008577.1 transcript variant X1 (Fig. 4A).
We next tested protein expression of the human WT TLR3 and
shorter TLR3 isoform by Western blot in F1 and F2 cells (from
synthetic mRNA made human iPSC-derived) demonstrating
expression of the WT TLR3 at 107 KDa and the putative
shorter TLR3 isoform at approximately 80 KDa missing the
LRR1-8 region important in receptor stabilization (Fig. 4A, Sup-
porting Information Fig. S8).
We next performed a comprehensive analysis of human
TLR3 gene expression levels in normal endogenous cell lines or
normal human neural tissue (frontal cortex or Hippocampus)
compared to various human iPSC derived cell types (from syn-
thetic mRNA method) to further confirm overexpression in
human iPSC derived cells (F2) and that differentiation or
reprograming method does not affect TLR3 expression levels
(Fig. 4B). RT-PCR gene expression analysis revealed that the
shorter TLR3 isoform is lower expressed in F1 cells than WT
TLR3 and is significantly higher upregulated in all reprogrammed
differentiated F2 cell types (CM, p = .0093; Definitive Endoderm –
DE, p = .033; NSC, p = .0044 and Motor Neurons – MN, p = .013)
(Fig. 4C). Interestingly, in addition to HFF other normal endogenous
cells such as bone marrow mesenchymal stem cells (BM MSC),
umbilical stem cells, or normal human brain tissue (hippocampus
and frontal cortex) have low levels of expression of WT TLR3 and
the shorter isoform TLR3, suggesting only reprogramed iPSC-
derived cells have elevated levels of the TLR3 isoform (Fig. 4C).
Therefore, we demonstrate that the overexpression of the
shorter TLR3 isoform in iPSC-derived cells is independent of
the methodology used because high levels of the isoform have
been found in most human iPSC generated by three different
methods (retrovirus, episomal vectors, or mRNA transfections).
Moreover, higher expression of the TLR3 isoform is indepen-
dent of the starting parent cell types because all somatic cell
types we tested, including HFF, cord blood cells, patient skin
fibroblasts, mesenchymal stem cells had low levels of expres-
sion of the human TLR3 isoform. Finally, the differentiation
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method did not affect levels of the TLR3 isoform expression
because we generated many different cell types from iPSC
(F2 cells included fibroblasts, NSC, MN, CM, and DE cells) and
most had significantly higher levels of expression of the TLR3
isoform (Fig. 4B, 4C).
Given that it has been previously published that a short
isoform of mouse TLR3, but different sequence and size to the
human TLR3 isoform described in this study can act as a sup-
pressor of the TLR3 innate immune pathway by competing
with the full length TLR3 protein in mouse astrocytes [31–33],
we next assessed the functional immune response of inflam-
mation cytokine IL6 in human iPSC-NSC to Poly (I:C) and LPS.
Assessment of IL6 expression levels by ELISA demonstrated
that iPSC-derived cells (F2 cells) have significantly higher levels
of expression of IL6 compared to F1 cells and a suppressed
innate immune response to viral infection (Poly IC 1ug/ml
overnight) in iPSC-derived cells (Fig. 4D). This suggests that
transplanted human iPSC-NSC would act as a cellular pump
producing physiologically higher levels of IL6 cytokine than is
normal in circulating blood and tissues and the cells would not
respond to viral infection (Fig. 4D).
Human TLR3 Isoform Functions to Suppress NF-KB p65
Signaling Pathway in Response to Virus (Poly IC)
Next, we performed a gain of function test in human iPSC-NSC
(F2 cells) to demonstrate the possible functional effect of the
human TLR3 isoform. We overexpressed WT TLR3 by lentiviral
methods in five synthetic mRNA made iPSC-NSC clones to out-
compete the TLR3 isoform and all NSC clones demonstrated high
levels of WT human TLR3 expression after infection (Fig. 5A).
Analysis of the expression of nuclear NF-KB p65 protein
Figure 3. Human TLR3 isoform transcription start site is hypomethylated in human iPSC-derived cells and exclusively expressed in
humans. In addition to human iPSC used in Figures 1 and 2, a HFF cell line (Life Technologies) was reprogrammed by transfection of syn-
thetic mRNA of the reprogramming factors to make six human iPSC lines and differentiated to NSC for further in depth analysis (charac-
terization of mRNA made hiPSC in a separate publication). (A): Methylome array raw data for all toll genes for F1 (HFF), six human iPSC,
and six F2 (NSC) cell lines. (B): Methylation profile of HFF (F1), iPSC, and NSC (F2) demonstrating four CpGs that containing a TSS in TLR3
is hypo-methylated in iPSC and NSC (F2 cells) but not in stating HFF (F1 cells). Methylation regions were considered significant using the
following bioinformatic criteria: (a) more than 20% difference in CpG methylation levels between F1 and F2, (b) more than one CpG island
affected, and (c) at least two hiPSC or NSC clones affected, (C) validation of hypomethylted TSS by pyrosequencing for two CpGs in human
iPSC confirming the CpG TSS region of an isoform TLR3 is hypomethylated. (D): Sketch of bioinformatics of the TLR3 WT and TLR3 isoform
demonstrating the TSS site (red) associated with acetylation (yellow) and DNAse hypersensitivity sites (dark blue) that indicate gene
expression and homology to other species (green). TLR3 isoform is uniquely expressed in humans and rhesus monkey. Lower panel:
Detailed sketch of the exons of the shorter TLR3 isoform discovered from the methylome array, compared to WT TLR3 for comparison.
Brown and blue arrows show gene regions showing RT PCR primer sequences. Abbreviations: HFF, human fibroblast; iPSC, induced plurip-
otent stem cells; NSC, neural stem cells; TLR3, toll like receptor protein 3; TSS, transcription start site; WT, wild type.
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phosphorylation by Western blot, an established marker of a
functional human TLR3 pathway, demonstrated that overex-
pression of human WT TLR3 in NSC could return sensitivity to
Poly (IC) treatment of NSC (Fig. 5B). Note that in control NSC
cells and in empty lentiviral control NSC (UB promoter only)
the NSC do not respond to Poly IC viral stimulation demon-
strated by no change in NF-KB p65 phosphorylation levels
(Fig. 5B). Overexpression of WT TLR3 in NSC and resulting
return to sensitivity to Poly IC stimulation supports the model
that the shorter TLR3 isoform is suppressing normal TLR3
function in NSC to viral insult (F2 cells) (Fig. 5B). Taken
together, we propose the model that in human iPSC-derived
cells that overexpress the shorter isoform of TLR3 competes
with full length TLR3 to suppress the innate inflammation sig-
nal transduction response in F2 cells to Poly IC (viral infection)
(Fig. 5C).
Figure 4. Human TLR3 isoform is overexpressed in most human iPSC derived cells not seen in normal human tissue or cells. (A): Expres-
sion of the shorter human isoform TLR3 with unique 50 UTR in red. Below the PCR of genomic DNA from human iPSC-derived NSC and
CM of the unique 50 UTR of the TLR3 isoform. Sequencing data of the PCR product for the 50 UTR of the human TLR3 isoform (in red)
with whole sequence found at or XM_017008577.1 transcript variant X1. Underlined regions are RT-PCR primer sequences used to detect
human isoform TLR3. Lower left panel: Western blot of TLR3 expression demonstrating expression of the WT TLR3 at 107 KDa and the
putative shorter TLR3 isoform at approximately 80 KDa in F1 cells (HFF) and F2 cells iPSC-derived NSC with schematic drawing of WT and
isoform human TLR3 missing the LRR1-8 region important in binding viral dsRNA and receptor stability. (B): Table of individual F1 and F2
cell lines for RT-PCR analysis of gene expression demonstrating that the human TLR3 isoform gene is overexpressed between 3 and 81 fold
more in F2 in five from six matched healthy cells (83%). In red, it is highlighted the exception healthy control patient sample (Epi-2) that
also did not have elevated AKT signal transduction protein levels in F2 cells seen in Figure 1. (C): Graph comparing WT TLR3 (FL: full
length) and isoform TLR3 gene expression in five normal healthy cells and tissues compared to synthetic mRNA made iPSC-derived cells
(dotted line divides normal from iPSC cells analyzed). Normal cells/tissues include: starting fibroblasts (HFF), normal endogenous BM
MSC, cord blood USSC, and normal tissues: normal hippocampus and frontal cortex human brain tissue demonstrating, demonstrating
low levels of gene expression of the shorter TLR3 isoform in normal tissues. Dotted line: Compared to the synthetic mRNA made repro-
gramed human iPSC differentiated into three different iPSC-derived cells: CM, NSC, ENDO, and MN demonstrating a significant increase in
gene expression of the shorter TLR3 isoform in all types of iPSC-derived cell types tested. (D): Graph of an ELISA assay of the functional
response of IL6 in human foreskin fibroblasts (F1, n = 2) and their mRNA made iPSC-derived neural stem cells (F2, n = 5) to LPS (100 ng/ml
over 24 hours) and Poly (I:C) stimulation (1 ug/ml) in triplicate, demonstrating a significantly suppressed IL6 immune response to Poly IC
(1 ug/ml over 24 hours) in iPSC-derived cells (F2 cells). Note: Synthetic mRNA made iPSC and derived NSC, CM, and DE have been charac-
terized and described in another paper currently under consideration for publication. Abbreviations: BM, bone marrow; CB, cord blood;
CM, cardiomyocytes; EPI, episomal made iPSC; HFF, human fibroblast; iPSC, induced pluripotent stem cells; LPS, lipopolysaccharide; MN,
motor neurons; MSC, mesenchymal stem cells; NSC, neural stem cells; RV, retroviral made iPSC; TLR3, toll like receptor protein 3; TSS,
transcription start site; USSC, umbilical stem cells; WT, wild type.
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DISCUSSION
There is a clear need to better understand the immune response
of autologous reprogramed human cells generated in vitro
before we embark on extensive clinical trials using human iPSC
to study and treat human disease. With that in mind we posit
the question: do patient cells that have been reprogramed into
iPSC-derived cells cause an immune response?
This study is based on a global proteomic and methylome
screening we performed using human skin cells (termed F1
cells) compared to their iPSC-derived cells (F2 cells) made from
three different reprogramming methods (retroviral, episomal,
and synthetic mRNA transfection). We reveal that WT TLR3
and a isoform of TLR3 are overexpressed in the majority (83%)
of F2 cells tested (five from six F1-F2 match lines tested) and
in all types of iPSC-derived cells (NSC, MN, DE, and CM) war-
ranting screening of iPSC-derived cell clones and removal in
disease modeling studies or clinical applications (Figs. 2D,
3B, 3C).
The data demonstrate that the cell reprogramming process
alters specific aspects of the innate immune response resulting
in a possible suppression of immunogenicity, supporting similar
findings recently described for human iPSC-derived cells [11, 34].
We discover two distinct states in human iPSC-derived cells
related to overexpression WT TLR3 and Isoform TLR3 that could
impinge on future clinical applications and disease modeling:
a. Unstimulated state: increased IL6 associated with increased WT
TLR3 expression in F2 cells (iPSC-derived cells) (Fig. 4C, 4D).
b. Stimulation with Poly IC: suppressed response to Poly IC
(Virus) in F2 cells due to overexpression of an isoform TLR3 that
can be rescued by overexpression of WT TLR3 (Fig. 5A–5C).
The higher levels of expression of the human TLR3 isoform
is central to understanding the altered immunogenicity of
human iPSC-derived cells. To mediate innate immune response
to virus infection and consequently the virus immunogenicity,
double-stranded RNA (dsRNA), a frequent by-product of virus
infection, should be recognized by TLR3. Simultaneously, the
PI3K-Akt (Fig. 1I) and NF-KB (Fig. 5B) pathways play an essential
role in TLR3-mediated gene induction [35]. The loss of inflam-
mation response of cells to bacterial (LPS) or viral (Poly (IC)
infection has been shown before in specific mouse neural cell
types that overexpress a different mutant mouse TLR3 isoform
to the human TLR3 isoform described in this study (not expressed
in mice) [31–33]. Interestingly, a recent study found that differen-
tiation of human iPSC results in a loss of immunogenicity and
leads to the induction of tolerance, despite expected antigen
expression differences between iPSC-derived versus original
somatic cells [11]. In further agreement with this study, it has
also been demonstrated that neural progenitor cells from human
iPSC generated less autogenous immune response, possibly by
Figure 5. Human TLR3 isoform functions to suppress NF-KB p65 signaling pathway in response to virus (Poly IC). (A): Graph of RT-PCR for WT
human TLR3 gene lentiviral overexpression in F2 cells (NSC that have high levels of expression of TLR3 isoform, (Black bars)). WT human TLR3
lentivirus was used to overexpress WT TLR3 in five (n = 5) F2 (NSC) clones to functionally outcompete with the TLR3 isoform observed to be
overexpressed in F2 cells (B). Western blot analysis of phosphorylated p65 (p-p65) in two NSC (F2 cells) clones. Gain of function with WT TLR3 in
F2 cells demonstrates the immune suppressive function of the short TLR3 isoform on TLR3 signal transduction in response to viral infection (Poly
IC). After lentiviral overexpression of full length TLR3, NSC recover responsiveness to stimulation by the viral analog Poly (IC), as seen by the
increase of phospho-p65 in the nuclear fraction. Control NSC were infected with a lentiviral empty vector (ubiquitin promoter only (LV-Ct) that
contained the same ubiquitin promoter as the wild type TLR3-LV vector). Loading controls are tubulin nuclear protein fraction. Representative
pictures of five NSC tested. (C): Schematic proposed model of full length TLR3 and the role of the shorter TLR3 isoform predominately expressed
in reprogrammed cells that acts to suppress the immune response. All experiments performed with n = 6 at least twice, unless stated. Abbrevia-
tions: iPSC, induced pluripotent stem cells; LV, lenti virus; NSC, neural stem cells; TLR3, toll like receptor protein 3; WT, wild type.
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altered toll like receptor pathway signaling they did not assess
[34]. This observation among others brings forward the interest-
ing possibility that human iPSC-derived cells may benefit from a
suppressed immunogenic microenvironment favoring initial sur-
vival and subsequent engraftment and tissue regeneration.
Research in animal models is well documented and work
by Araki et al., working mainly with skin and bone marrow
transplant in mice, demonstrates mouse iPSC-derived CM cause
T cell infiltration when transplanted under the skin of syngeneic
mice [13]. Todorova et al., found that the location of iPSC trans-
plantation can affect the immune outcome because the kidney
is immune privileged, highlighting that differences between
studies could be explained by experimental procedure and design
differences [14]. The group by Almeida et al., found that mouse
iPSC-derived endothelial cells are intrinsically immunogenic in
syngeneic mice, but are immune tolerated by overexpressing
immune suppressive molecule IL-10; however, their study did
not assess TLR3 expression levels [11].
The altered TLR3 innate immune response of human in vitro
iPSC-derived cells raises a number of issues to be considered for
future cell transplantation in humans.
i. This may allow for human iPSC-derived cells to be used not
only as an autologous cell therapy but also in a limited
capacity as an allogenic cell therapy because of a sup-
pressed immunogenic microenvironment favoring initial sur-
vival and subsequent engraftment and tissue regeneration.
ii. Evasion of the immune system is a key hallmark of cancer
and suppression of the immune response of iPSC-derived
cells may impose a long-term cancer threat not previously
considered. This consideration is considerably enhanced by
recent work that demonstrates the AKT pathway induces a
transcriptional program via C/EBP that promotes immune
suppression during inflammation and tumor growth [36].
Inhibition of the AKT driven signaling pathway prolongs NFκB
activation, which in turn inhibits C/EBPβ activation promoting
an immunostimulatory transcriptional program that restores
CD8+ T cell activation, cytotoxicity, and synergizes with check-
point inhibitor therapy to promote tumor regression and
extend survival in mouse models of cancer [36].
iii. Transplantation of iPSC-derived cells that constitutively express
physiologically higher levels of inflammatory cytokine IL6
(Fig. 4D) may result in long-term adverse effects in the body.
This may have important implications in future human iPSC
clinical trials such as the RIKEN AMD-RPE clinical trial [17, 18].
iv. The need to screen patient iPSC and derived cells using
global gene analysis “omics” for alterations in the genome
of patient cells that include expression levels of TLR3 and
its shorter TLR3 isoform identified in this work. Indeed,
impaired TLR3 function to herpes simple virus (HSV-1) infec-
tion in the CNS has important implications in the pathogene-
sis of HSV-1 encephalitis (HSE) in children [37].
Interestingly, activation of innate immunity is required for
efficient nuclear reprogramming to iPSC via the TLR3 receptor
pathway using either viral or non-viral methods [38]. The
authors find that by using gain and loss of function studies,
the TLR3 pathway enables efficient induction of pluripotency
by viral or non-viral synthetic mRNA transfection approaches.
Stimulation of TLR3 causes rapid and global changes in the
expression of epigenetic modifiers to enhance chromatin
remodeling and nuclear reprogramming. Furthermore, they con-
clude that activation of inflammatory pathways are required for
efficient nuclear reprogramming in the induction of pluripotency
[38]. Our finding suggests that the TLR3 pathway, important for
achieving cell pluripotency, is not re-set to the correct expression
levels in iPSC-differentiated cells (F2) and that this then results in
altered cytokine secretion leading to possible immune suppression
of transplanted iPSC-derived cells (Figs. 4, 5). We demonstrate that
the mechanism of constitutive expression of the shorter TLR3 iso-
form is most likely at an epigenetic level, resulting in hypomethyla-
tion of a TSS producing a shorter TLR3 isoform that competes to
suppress normal full length TLR3 signal transduction function
(Figs. 3, 4).
In conclusion, the data demonstrate that the cell reprogram-
ming process alters the immune response of most iPSC-derived
cells highlighting human TLR3 isoform overexpression that func-
tions to suppress innate immune signal transduction and provides
an insight for future clinical applications of autologous human iPSC-
derived cell transplantation. We propose that screening human
iPSC clones and their derived cells for alterations in the genome
of patient cells that include expression levels of human TLR3
and its shorter TLR3 isoform identified in this work is essential
before embarking on “first in man” clinical trials or human
disease modeling using human iPSC.
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